GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients
19 sept. 2023 09h00 HE
|
GeoVax, Inc.
Data Published From Phase 2 Open-Label Study of GEO-CM04S1 ATLANTA, GA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing...
Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology
18 sept. 2023 09h05 HE
|
Atriva Therapeutics GmbH
Atriva Therapeutics and Canadian Biocure Technologies, Inc. entered into an exclusive letter agreement for a reverse takeover transaction. Upon successful completion of the transaction, the...
COVID-19 Diagnostics Market Revenue to Cross USD 45.8 billion by 2031, Registering a Negative 7.9% CAGR Says, Transparency Market Research
13 sept. 2023 06h20 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The COVID-19 diagnostics market was estimated to have acquired US$ 79.8 billion in 2021....
AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference
05 sept. 2023 09h05 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, Chief Executive Officer of AIM, will present...
InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)
30 août 2023 07h30 HE
|
InflaRx N.V.
MAA for vilobelimab was submitted in JulyMAA has been validated by EMA and is now under reviewRegulatory submission based on pivotal data from PANAMO Phase III trialCompany announces attendance at...
DriveThru Urgent Care flagship location now open in Atlanta
24 août 2023 12h00 HE
|
Viral Solutions LLC
ATLANTA, Aug. 24, 2023 (GLOBE NEWSWIRE) -- DriveThru Urgent Care — by Viral Solutions — is now seeing patients at its flagship location on Howell Mill Road in Atlanta. The practice treats patients...
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Danaher Corporation Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – DHR
20 août 2023 13h52 HE
|
The Rosen Law Firm PA
NEW YORK, Aug. 20, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Danaher Corporation (NYSE: DHR) between April 21, 2022 and...
AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update
15 août 2023 06h45 HE
|
AIM ImmunoTech Inc.
– Continued operational execution across pipeline towards multiple clinical and regulatory value-driving milestones expected in the second half of 2023 – Company to host conference call and...
InflaRx Reports Second Quarter 2023 Financial Results & Operating Update
10 août 2023 07h30 HE
|
InflaRx N.V.
• Quarter highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab) in the United States • Oral C5aR inhibitor INF904 progressing in...
AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast
09 août 2023 09h05 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss...